Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916926 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| SCHEMBL8931534 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| SCHEMBL8698267 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| SCHEMBL29566189 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| SCHEMBL5436410 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| SCHEMBL7377158 | 0.90 | SRD5A1 (0.82) | SRD5A1SRD5A2 | |
| SCHEMBL8348117 | 0.90 | SRD5A1 (0.82) | SRD5A1SRD5A2 | |
| SCHEMBL7377153 | 0.90 | SRD5A1 (0.82) | SRD5A1SRD5A2 | |
| SCHEMBL8931508 | 0.89 | SRD5A1 (0.81) | SRD5A1SRD5A2 | |
| SCHEMBL916892 | 0.89 | SRD5A1 (0.81) | SRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371367-A1 | Method of treating men with testosterone supplement and 5alpha reductase inhibitor | MERCK SHARP & DOHME (I.A.) CORP. (US) | 2011-10-05 | — | — | EP | claimed |
| US-20110136769-A1 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2011-06-09 | — | — | US | claimed |
| US-20110092470-A1 | METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION | MEEHAN ALAN | 2011-04-21 | — | — | US | claimed |
| EP-2305352-A1 | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders | Merck Sharp & Dohme Corp. (US) | 2011-04-06 | — | — | EP | claimed |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | MEEHAN ALAN | 2011-01-20 | — | — | US | claimed |
| EP-1865955-A4 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | claimed |
| EP-1865955-A2 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | Merck & Co., Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006104762-A2 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 2006-10-05 | — | — | WO | claimed |
| US-5872126-A | ENZYME INHIBITORS FOR TREATMENT OF PREMATURE LABOR | MERCK & CO., INC. (US) | 1999-02-16 | — | — | US | claimed |
| US-5585383-A | SKIN DISORDERS; ALOPECIA; CRYSTALLIZATION FROM A OIL | MERCK & CO., INC. (US) | 1996-12-17 | — | — | US | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996012705-A1 | 7-SUBSTITUTED 4-AZA CHOLANIC ACID DERIVATIVES AND THEIR USE | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| US-5512555-A | Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one | MERCK & CO., INC. (US) | 1996-04-30 | — | — | US | claimed |
| WO-1996008239-A1 | USE OF 5-ALPHA-REDUCTASE INHIBITORS TO INCREASE HDL CHOLESTEROL LEVELS | MERCK & CO., INC. (US) | 1996-03-21 | — | — | WO | claimed |
| WO-1996003129-A1 | METHOD OF TREATING SWEAT-RELATED CONDITIONS | MERCK & CO., INC. (US) | 1996-02-08 | — | — | WO | claimed |
| WO-1995013815-A1 | COMBINATION METHOD FOR THE TREATMENT OF PATTERNED ALOPECIA | MERCK & CO., INC. (US) | 1995-05-26 | — | — | WO | claimed |
| WO-1995013077-A1 | 7β-SUBSTITUTED-4-AZA-5α-CHOLESTAN-3-ONES AS SELECTIVE 5α-REDUCTASE 1 INHIBITORS | MERCK & CO., INC. (US) | 1995-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136769-A1 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | ADRA1D, ADRB1, AGER | SRD5A1 17/4885SRD5A2 26/4885 |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | CYP17A1, SHBG, CYP21A2 | SRD5A1 10/4885SRD5A2 4/4885 |
| US-20110092470-A1 | METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION | ADRA1D, ADRB1, AGER | SRD5A1 37/4885SRD5A2 53/4885 |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | CYP17A1, SHBG, CYP21A2 | SRD5A1 10/4885SRD5A2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.